An advisory committee opted not to support the FDA in its acceptance of using two psychiatric drugs in children. The panel criticized agency regulations on prescribing Johnson & Johnson's Risperdal and Eli Lilly and Co.'s Zyprexa for children and called for more efforts to curb their growing use, particularly for off-label treatment of ADHD.

Full Story:

Related Summaries